Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash from Financing Activities (2018 - 2025)

Inmune Bio's Cash from Financing Activities history spans 8 years, with the latest figure at $22.3 million for Q2 2025.

  • For Q2 2025, Cash from Financing Activities rose 71.35% year-over-year to $22.3 million; the TTM value through Sep 2025 reached $25.5 million, up 43.16%, while the annual FY2024 figure was $18.2 million, 531.03% up from the prior year.
  • Cash from Financing Activities for Q2 2025 was $22.3 million at Inmune Bio, up from $5.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $52.9 million in Q3 2021 and bottomed at -$2.5 million in Q4 2023.
  • The 5-year median for Cash from Financing Activities is $9.8 million (2024), against an average of $12.8 million.
  • The largest annual shift saw Cash from Financing Activities surged 316366.67% in 2021 before it crashed 97.44% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $52.9 million in 2021, then crashed by 98.62% to $729000.0 in 2022, then tumbled by 442.94% to -$2.5 million in 2023, then rose by 16.88% to -$2.1 million in 2024, then surged by 1171.75% to $22.3 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Cash from Financing Activities are $22.3 million (Q2 2025), $5.3 million (Q1 2025), and -$2.1 million (Q4 2024).